deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT03472040

A Long Term Safety Study of BCX7353 in Hereditary Angioedema (APeX-S)

An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema

Sponsor: BioCryst Pharmaceuticals

Interventions BCX7353
Updated 23 times since 2018 Last updated: May 23, 2023 Started: Feb 16, 2018 Primary completion: Apr 27, 2022 Completion: Apr 27, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03472040, this PHASE2/PHASE3 trial focuses on HAE and Hereditary Angioedema and remains completed. Sponsored by BioCryst Pharmaceuticals, it has been updated 23 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2023 · 25 months · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

23 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Feb 2023 — Jul 2023 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not RecruitingCompleted

Show 18 earlier versions
  1. Jan 2021 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: RecruitingActive Not Recruiting

  2. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  3. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE2_PHASE3

  4. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE2_PHASE3

  5. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2_PHASE3

  6. Jan 2020 — Apr 2020 [monthly]

    Recruiting PHASE2_PHASE3

  7. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2_PHASE3

  8. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE2_PHASE3

  9. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE2_PHASE3

  10. Apr 2019 — Aug 2019 [monthly]

    Recruiting PHASE2_PHASE3

  11. Dec 2018 — Apr 2019 [monthly]

    Recruiting PHASE2_PHASE3

  12. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2_PHASE3

  13. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE2_PHASE3

  14. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE2_PHASE3

  15. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2_PHASE3

  16. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2_PHASE3

  17. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2_PHASE3

  18. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BioCryst Pharmaceuticals
Data source: BioCryst Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .